Table 1 Characteristics of study population

 n of DXA

678

232

339

107

 Age (years)

62.67±8.02

54.80±2.78

63.56±2.81

76.92±5.08

 n of osteoporosis by DXA (n %)

358(52.8%)

67(28.8%)

210(61.9%)

81(75.7%)

<0.001^*

 n of osteopenia by DXA (n %)

269(39.7%)

138(59.5%)

113(33.3%)

18(16.8%)

<0.001^*

 n of patients with fragility VFs in osteoporosis (n %)

221(61.7%)

32(47.8%)

135(64.3%)

54(66.7%)

0.031^*

 n of patients with fragility VFs in osteopenia (n %)

83(30.9%)

41(29.7%)

38(38.1%)

4(22.2%)

0.210

 n of patients with fragility VFs in normal BMD (n %)

6(11.8%)

3(11.1%)

3(18.75%)

0

 n of osteoporosis by DXA and VRA (n %)

447(65.9%)

111(47.8%)

251(74.1%)

85(79.4%)

<0.001^*

 n of DXA

567

233

263

71

 Age (years)

61.72±8.04

54.07±2.87

64.46±2.59

76.65±4.66

 n of osteoporosis by DXA (n %)

106(18.7%)

37(15.9%)

45(17.1%)

24(33.8%)

0.002^*

 n of osteopenia by DXA (n %)

265(46.7%)

97(41.6%)

137(52.1%)

31(43.7%)

0.057

 n of patients with fragility VFs in osteoporosis (n %)

50(47.2%)

13(35.1%)

17(37.8%)

20(83.3%)

<0.001^*

 n of patients with fragility VFs in osteopenia (n %)

81(30.6%)

31(32.0%)

40(29.2%)

10(32.3%)

0.895

 n of patients with fragility VFs in normal BMD (n %)

43(21.9%)

21(21.2%)

18(22.2%)

4(25.0%)

 n of osteoporosis by DXA and VRA (n %)

230(40.6%)

89(38.2%)

103(39.2%)

38(53.5%)

0.058